Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

BRANDON LENOX

Allopathic & Osteopathic Physicians Anesthesiology

NPI
1710023098
CMS profile
469116
Location
MAITLAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$2,161.67

16 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $1,564.57 4
Food and Beverage $597.10 12

By paying entity

PY2024 · entire year · sorted by reported total

Paying entityAmountRecords
Eli Lilly and Company $1,342.29 8
Merck Sharp & Dohme LLC $819.38 8

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

BRANDON LENOX

NPI 1710023098 · CMS profile ID 469116

Allopathic & Osteopathic Physicians / Anesthesiology

MAITLAND, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1710023098?year=2024&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
BRANDON LENOX, NPI 1710023098, CMS profile ID 469116. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1710023098?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). BRANDON LENOX, NPI 1710023098, CMS profile ID 469116. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1710023098?year=2024&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
BRANDON LENOX, NPI 1710023098, CMS profile ID 469116, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–16 of 16 matching records. This page contains 16 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1710023098?year=2024&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

16 matching records · $2,161.67 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 16 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–16 of 16.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $55.0011/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141625338 CMS
Merck Sharp & Dohme LLC $29.9711/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141625429 CMS
Merck Sharp & Dohme LLC $202.2711/13/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141625340 CMS
Merck Sharp & Dohme LLC $59.9411/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141625427 CMS
Merck Sharp & Dohme LLC $149.9311/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141625431 CMS
Merck Sharp & Dohme LLC $55.0011/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141625441 CMS
Merck Sharp & Dohme LLC $65.0011/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141846159 CMS
Merck Sharp & Dohme LLC $202.2711/12/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141625433 CMS
Eli Lilly and Company $12.0808/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136070137 CMS
Eli Lilly and Company $35.9008/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136072523 CMS
Eli Lilly and Company $31.3008/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136073007 CMS
Eli Lilly and Company $336.2208/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136073603 CMS
Eli Lilly and Company $30.3808/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136073605 CMS
Eli Lilly and Company $12.6008/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136073849 CMS
Eli Lilly and Company $823.8108/05/2024 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1136076043 CMS
Eli Lilly and Company $60.0007/30/2024 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1155176807 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $11.87 1
PY2021 $14.90 1
PY2022 $289.02 3
PY2023 $141.36 2
PY2024 $2,161.67 16
PY2025 $3,301.84 7

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $13,276,611.80 216
PY2024 Principal investigator $6,638,229.38 94
PY2023 Recipient $18,535.52 1
PY2023 Principal investigator $6,796,584.13 63
PY2022 Recipient $75,198.00 3
PY2022 Principal investigator $5,184,921.00 42
PY2021 Recipient $4,330.51 1
PY2021 Principal investigator $6,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

64 records in PY2023

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $926.50 12/31/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998413575
Principal investigator 1 ABBVIE INC. $94.50 12/31/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998413731
Principal investigator 1 Janssen Research & Development, LLC $9,292.00 12/28/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986159407
Principal investigator 1 ABBVIE INC. $1,000.00 12/13/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998411555
Principal investigator 1 BioXcel Therapeutics, Inc. $35,165.00 11/29/2023 Non-covered Recipient Entity
K-2 MEDICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY ANDSAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD INSUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEASTMODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING No dispute reported 06/30/2026 1057507219
Principal investigator 1 Janssen Research & Development, LLC $800.00 11/20/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986159405
Principal investigator 1 ABBVIE INC. $200.00 11/08/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998407179
Principal investigator 1 Bavarian Nordic A/S $13,215.00 11/02/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703485
Principal investigator 1 BioXcel Therapeutics, Inc. $35,000.00 10/26/2023 Non-covered Recipient Entity
K-2 MEDICAL RESEARCH LLC
A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EFFICACY ANDSAFETY STUDY OF PRN DOSING OF BXCL501 OVER A 12 WEEK TREATMENT PERIOD INSUBJECTS WITH AGITATION ASSOCIATED WITH DEMENTIA WHO REQUIRE AT LEASTMODERATE TO FULL ASSISTANCE WITH ACTIVITIES OF DAILY LIVING No dispute reported 06/30/2026 1057507085
Principal investigator 1 Janssen Research & Development, LLC $2,520.00 10/23/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986159403
Principal investigator 1 Bavarian Nordic A/S $16,891.00 10/10/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703545
Principal investigator 1 Janssen Research & Development, LLC $2,520.00 10/06/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986159401
Principal investigator 1 Janssen Research & Development, LLC $9,871.00 09/11/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986159399
Principal investigator 1 Bavarian Nordic A/S $1,243.00 09/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703515
Principal investigator 1 ABBVIE INC. $17,536.00 09/05/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998398327
Principal investigator 1 Bavarian Nordic A/S $2,365.00 09/01/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703473
Principal investigator 1 Bavarian Nordic A/S $5,267.00 08/23/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703639
Principal investigator 1 Bavarian Nordic A/S $1,075.00 08/18/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703595
Principal investigator 1 Janssen Research & Development, LLC $54,931.00 08/11/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986159397
Principal investigator 1 Bavarian Nordic A/S $7,477.00 08/10/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703539
Principal investigator 1 Bavarian Nordic A/S $6,616.00 07/26/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703663
Principal investigator 1 Bavarian Nordic A/S $9,029.00 07/18/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703601
Principal investigator 1 Bavarian Nordic A/S $22,658.00 07/11/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703551
Principal investigator 1 Eli Lilly and Company $11,570.26 07/11/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038107023
Principal investigator 1 Bavarian Nordic A/S $5,911.00 07/04/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703503
Principal investigator 1 Bavarian Nordic A/S $3,070.00 06/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703675
Principal investigator 1 ABBVIE INC. $3,000.00 06/21/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH MAITLAND LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998387843
Principal investigator 1 Bavarian Nordic A/S $11,669.00 06/20/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703619
Principal investigator 1 Janssen Research & Development, LLC $800.00 06/15/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986159395
Principal investigator 1 Bavarian Nordic A/S $13,019.00 06/13/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703565
Principal investigator 1 Bavarian Nordic A/S $8,504.00 06/08/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703521
Principal investigator 1 Janssen Research & Development, LLC $14,265.00 06/02/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986159393
Principal investigator 1 Bavarian Nordic A/S $1,673.00 05/30/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703687
Principal investigator 1 Bavarian Nordic A/S $645.00 05/24/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703645
Principal investigator 1 Bavarian Nordic A/S $430.00 05/19/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703607
Principal investigator 1 Bavarian Nordic A/S $3,991.00 05/16/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703583
Principal investigator 1 Bavarian Nordic A/S $3,823.00 05/09/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703533
Principal investigator 1 Bavarian Nordic A/S $362.00 05/09/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703979
Principal investigator 1 Janssen Research & Development, LLC $30,418.00 05/08/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A Randomized Double blind Placebo controlled Parallel group Multi Center Study to Assess the Efficacy and Safety of JNJ63733657 an Antitau Monoclonal Antibody in Participants with Early Alzheimer's Disease No dispute reported 06/30/2026 986159391
Principal investigator 1 Bavarian Nordic A/S $7,908.00 05/03/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703491
Principal investigator 1 Bavarian Nordic A/S $10,179.00 04/26/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703657
Principal investigator 1 Bavarian Nordic A/S $17,489.00 04/18/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703589
Principal investigator 1 Bavarian Nordic A/S $5,926.00 04/13/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703559
Principal investigator 1 Bavarian Nordic A/S $13,760.00 04/04/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703497
Principal investigator 1 Eli Lilly and Company $2,334,850.00 03/30/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1038110279
Principal investigator 1 Bavarian Nordic A/S $5,590.00 03/29/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703681
Principal investigator 1 Bavarian Nordic A/S $7,861.00 03/21/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703627
Principal investigator 1 Bavarian Nordic A/S $34,192.00 03/15/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703571
Principal investigator 1 ABBVIE INC. $10,500.00 03/09/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
Study to Assess Adverse Events, Change in Disease Activity and How Oral ABBV-552 Capsules Moves Through the Body of Participants Aged 50 to 90 Years With Mild Alzheimers Disease No dispute reported 06/30/2026 998373213
Principal investigator 1 Bavarian Nordic A/S $2,439.00 02/28/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703669
Principal investigator 1 Bavarian Nordic A/S $6,450.00 02/22/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703633
Principal investigator 1 Bavarian Nordic A/S $6,235.00 02/16/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703577
Principal investigator 1 Bavarian Nordic A/S $6,309.00 02/09/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703527
Principal investigator 1 Bavarian Nordic A/S $9,796.00 02/02/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703479
Principal investigator 1 Eli Lilly and Company $26,764.78 01/26/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1038106209
Principal investigator 1 Bavarian Nordic A/S $25,115.00 01/25/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703651
Principal investigator 1 Eli Lilly and Company $711.99 01/24/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A STUDY OF DIFFERENT DONANEMAB (LY3002813) DOSING REGIMENS IN ADULTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 6) No dispute reported 06/30/2026 1038104845
Principal investigator 1 Bavarian Nordic A/S $14,170.00 01/20/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703613
Recipient Eli Lilly and Company $18,535.52 01/10/2023 Covered Recipient Physician A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038047579
Principal investigator 1 Eli Lilly and Company $14,271.10 01/10/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1038130949
Principal investigator 1 Eli Lilly and Company $556,019.00 01/09/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY MEASURED BY AMYLOID REDUCTION OF LY3372993 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1038105501
Principal investigator 1 Bavarian Nordic A/S $36,897.00 01/06/2023 Non-covered Recipient Entity
ACCELLACARE US INC
A Randomized, Double-blind, Phase 3 Trial to Assess Clinical Efficacy, Safety and Reactogenicity of the Recombinant MVA-BN -RSVVaccine in Adults 60 Years of Age No dispute reported 06/30/2026 988703509
Principal investigator 1 Eli Lilly and Company $337,043.00 01/03/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
ASSESSMENT OF SAFETY TOLERABILITY AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1038103397
Principal investigator 1 Eli Lilly and Company $2,937,266.00 01/03/2023 Non-covered Recipient Entity
K2 MEDICAL RESEARCH LLC
A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) No dispute reported 06/30/2026 1038107013